Lipidil-Ter

Fenofibrate, the active ingredient in Lipidil-Ter, is a fibrate presented as a tablet for oral use. It lowers elevated triglyceride levels and improves cholesterol profiles in adults with dyslipidemia. GNH USA supplies Lipidil-Ter as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fenofibrate is indicated for disorders of lipid metabolism that increase cardiovascular risk. - Hypertriglyceridemia: reduces very‑low‑density lipoprotein triglycerides and lowers plasma triglyceride concentrations. - Mixed dyslipidemia: improves the overall lipid profile by decreasing triglycerides and modestly raising HDL‑cholesterol. - Primary hypercholesterolemia: contributes to lowering total cholesterol and LDL‑cholesterol when used as part of a comprehensive treatment plan.

Fenofibrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Abdominal pain: mild to moderate discomfort in the stomach area. - Nausea: feeling of queasiness, sometimes leading to vomiting. - Dyspepsia: indigestion or heartburn. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Severe liver injury: marked elevation of liver enzymes or hepatic failure. - Pancreatitis: inflammation of the pancreas. - Allergic reactions: rash, itching, or anaphylaxis. - Myopathy: muscle pain or weakness. - Gallstones: formation of biliary calculi.

Before initiating therapy, consider the following safety measures. - Monitor liver function: obtain baseline and periodic liver enzyme tests. - Monitor renal function: assess serum creatinine and eGFR, especially in patients with existing kidney disease. - Assess lipid profile: evaluate triglyceride and cholesterol levels to gauge therapeutic response. - Review concomitant medications: avoid strong CYP2C9 inhibitors and drugs that increase myopathy risk. - Evaluate for gallbladder disease: fenofibrate may promote gallstone formation. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Fenofibrate can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Cyclosporine: increased risk of myopathy and renal toxicity. - Gemfibrozil: additive risk of severe muscle toxicity, including rhabdomyolysis. - Strong CYP2C9 inhibitors (e.g., fluconazole): may raise fenofibrate plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): potential enhancement of anticoagulant effect, requiring INR monitoring. - Statins: increased likelihood of muscle-related adverse events. - Bile‑acid sequestrants: may reduce fenofibrate absorption, lowering efficacy. - Thiazide diuretics: possible rise in serum creatinine. - ACE inhibitors: may affect renal function when combined.